Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

roche - lévodopa 100 mg; bensérazide base 25 mg sous forme de : bensérazide (chlorhydrate de) 28 - gélule - 100 mg - pour une gélule > lévodopa 100 mg > bensérazide base 25 mg sous forme de : bensérazide (chlorhydrate de 28,5 mg - antiparkinsoniens dopaminergiques - classe pharmacothérapeutique antiparkinsoniens dopaminergiques - code atc : n04ba02.ce médicament est préconisé dans la maladie de parkinson et dans certaines maladies neurologiques présentant les mêmes symptômes.

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

roche - lévodopa 100 mg; bensérazide base 25 mg sous forme de : bensérazide (chlorhydrate de) 28 - comprimé - 100 mg - pour un comprimé > lévodopa 100 mg > bensérazide base 25 mg sous forme de : bensérazide (chlorhydrate de 28,48 mg - antiparkinsoniens dopaminergiques - classe pharmacothérapeutique antiparkinsoniens dopaminergiques - code atc : n04ba02.ce médicament est préconisé dans la maladie de parkinson et dans certaines maladies neurologiques présentant les mêmes symptômes.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base; levodopa 100mg;   - capsule - 125 mg - active: benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base levodopa 100mg   excipient: gelatin indigo carmine iron oxide red magnesium stearate microcrystalline cellulose povidone purified talc titanium dioxide - madopar is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 57mg equivalent to to 50 mg benserazide base; levodopa 200mg;   - capsule - 250 mg - active: benserazide hydrochloride 57mg equivalent to to 50 mg benserazide base levodopa 200mg   excipient: gelatin indigo carmine iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose povidone purified talc titanium dioxide - madopar is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base; levodopa 50mg;   - capsule - 62.5 mg - active: benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base levodopa 50mg   excipient: gelatin indigo carmine iron oxide black magnesium stearate mannitol microcrystalline cellulose povidone purified talc titanium dioxide - madopar is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base; levodopa 50mg;   - dispersible tablet - 62.5 mg - active: benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base levodopa 50mg   excipient: citric acid magnesium stearate maize starch microcrystalline cellulose - madopar rapid is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism. madopar rapid is a formulation which is suitable for patients with dysphagia (difficulties in swallowing) or who require a formulation with a more rapid onset of action, e.g. patients suffering from early morning and afternoon akinesia, or who exhibit "delayed on" or "wearing off" phenomena.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base; levodopa 100mg;   - modified release capsule - 125 mg - active: benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base levodopa 100mg   excipient: calcium hydrogen phosphate dihydrate gelatin hydrogenated vegetable oil hypromellose indigo carmine iron oxide yellow magnesium stearate mannitol povidone purified talc titanium dioxide - madopar hbs is indicated for patients presenting with all types of fluctuation in response, especially those related to fluctuations in plasma levels (i.e. "peak dose dyskinesia" and "end of dose deterioration") and for better control of nocturnal symptoms

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

roche - bensérazide base - comprimé - 25 mg - composition pour un comprimé > bensérazide base : 25 mg . sous forme de : chlorhydrate de bensérazide 28,25 mg > lévodopa : 100 mg

Finland - finsk - Fimea (Suomen lääkevirasto)

orifarm healthcare a/s - benserazide hydrochloride, levodopa - tabletti - 100 mg / 25 mg - levodopa ja dekarboksylaasin estäjä

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

benserazidehydrochloride 28,5 mg/stuk samenstelling overeenkomend met ; benserazide 25 mg/stuk ; levodopa 100 mg/stuk - tablet - calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460(i)) ; crospovidon (e 1202) ; docusaat natrium ; ethylcellulose (e 462) ; ijzeroxide rood (e 172) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; maÏszetmeel, gepregelatineerd ; siliciumdioxide (e 551), calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460) ; crospovidon (e 1202) ; docusaat natrium ; ethylcellulose (e 462) ; ijzeroxide rood (e 172) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; maÏszetmeel, gepregelatineerd ; siliciumdioxide (e 551)